Capricor Therapeutics Shares Surge on Positive Clinical Trial Data

Key Facts

1Capricor Therapeutics shares rose following the release of positive long-term clinical data for its lead cellular therapy.

Capricor Therapeutics shares rose following the release of positive long-term clinical data for its lead cellular therapy. Benzinga reported that the stock surge was driven by investor optimism regarding the efficacy and safety profile shown in the newly released results for the company's primary therapeutic candidate.

CAPR closed at $8.57 on September 29, 2026, with the stock reaching a day high of $8.97 against a low of $8.50. The positive price action reflects the significance of clinical trial milestones as a primary catalyst for mid-cap biotechnology entities.